Ares Financial Consulting
RVMD icon

Ares Financial Consulting’s Revolution Medicines RVMD Stock Holding History

Ares Financial Consulting’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.98K Hold
34
– – ﹤0.01% 632
2026
Q2 		$6.37K Buy
+34
New +$4.97K ﹤0.01% 659

Other funds holding RVMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Ares Financial Consulting's RVMD Position: Q3 2026 in Review

Ares Financial Consulting held its Revolution Medicines (RVMD) position steady in Q3 2026 at 34 shares worth $6.98K. The position accounts for ﹤0.01% of the portfolio, ranked #632.

Ares Financial Consulting first reported a position in RVMD in Q2 2026 and has held it in 2 quarters since. 415 funds tracked by Wall St. Rank hold RVMD as of Q3 2026.

  • Ares Financial Consulting held 34 shares of Revolution Medicines worth $6.98K as of Q3 2026.
  • Ares Financial Consulting left its Revolution Medicines share count unchanged in Q3 2026.
  • Revolution Medicines made up ﹤0.01% of Ares Financial Consulting's portfolio in Q3 2026, its #632 holding.
  • Ares Financial Consulting first reported a position in Revolution Medicines in Q2 2026 and has held it in 2 quarters since.
  • 415 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.